Research and Development

Our R&D department leverages advanced technologies and personalized approach to create breakthrough solutions for chronic wounds and skin diseases.

Leading the future of wound care

At Flen Health, we are dedicated to revolutionizing the treatment of wounds and skin diseases through our research and development efforts.

One of our flagship innovations, Flaminal^®, utilizes enzymes within an alginate environment to effectively treat difficult-to-heal wounds, accelerating the healing process. Our enzyme-technology platform also supports the development of new enzyme-based biopharmaceuticals, targeting the most challenging wound and skin conditions.

R&D Strategy: from concept to market

Understanding the unmet need and complexity of wound and skin environment is central to our R&D strategy. Traditional approaches often fail to capture the dynamic biological processes involved in disease progression and during healing. At Flen Health and in collaboration with external partners, we have developed a platform technology for the identification, development, and registration of protein-based treatments, transforming the lives of patients with chronic wounds and skin conditions.

We employ an innovative dual approach, combining advanced digital modeling with in vitro research.

1. From insight to target

By combining disease insights with a range of scientific skills, including functional genomics, structural and molecular biology, and computational methods, we gain a deeper understanding of why some wounds heal while others become chronic. This multidisciplinary approach helps identify key targets within disease pathways. These targets have a clear, testable link to the underlying causes of the condition and their impact on patients, allowing for more precise and effective interventions.

2. From target to treatment

Integrating the potential disease targets into advanced in-vitro models (incl. our artificial skin model), we replicate the complex environment of wound healing. Combining recombinant engineering capabilities with a wide-exertise in formulation development of different therapeutic modalities (including small molecules and proteins), we are able to to observe and analyze treatment reactions in a controlled setting.

By integrating these advanced technologies, we tailor treatments to the specific needs of patients, ensuring our solutions are both effective and personalized.

R&D Innovative Center

The Flen Health Innovation Center is dedicated to driving advancements in wound care through continuous investment in research and development.

With over €7.1 million in external R&D grants in the past five years and 10% of our workforce focused on R&D, we are at the forefront of developing patented technologies, including innovations like Flamigel^® and Flaminal^®.

Our commitment to innovation is recognized globally, as evidenced by receiving the EU Innovation Company Label and an EU-guaranteed loan.

Through these efforts, we create cutting-edge solutions that improve patient care worldwide.

Evolving product portfolio

Flen Health is constantly evolving our product portfolio to stay at the forefront of wound care. One of our latest developments is VES 0, an enhancement of our Flaminal^® technology.

This product utilizes a novel patent that modulates inflammation, transitioning chronic wounds from a persistent inflammatory state to an effective healing state. Following promising preclinical results, we are preparing for Phase 0 clinical trials in the upcoming year.

R&D Grants

Flen Health is dedicated to advancing healthcare innovation through various grants that support groundbreaking research and development in areas such as wound care and antimicrobial resistance.

Our grants focus on several key areas, including biological wound treatment research, exploring new pathways for treating chronic wounds, developing solutions for radiation-induced injuries, advancing technologies for hyperpigmentation disorders, and benefiting from EU-backed financial support for innovation.

Discover more

Addressing Antimicrobial Resistance

Antibiotic resistance is a critical challenge in wound care, particularly in chronic wounds like diabetic foot ulcers, which create ideal conditions for bacterial growth. Flen Health tackles this issue with innovative enzyme systems.

Our GLG-based treatments, unlike traditional antimicrobials, are designed to minimize resistance, offering a safer and more effective solution. By leveraging our deep understanding of AMR at the cellular level, we have patented enzyme-based treatments that not only reduce resistance risks but also improve patient outcomes and lower infection rates in chronic wounds.

Our research-driven commitment to patients

At Flen Health, our R&D process is built around a commitment to improving patient outcomes through innovation and technology. Our comprehensive approach includes:

1. Identifying Clinical Needs:
We begin by thoroughly understanding the underlying biology of wound and skin conditions.

2. Leveraging Technology:
Our technology platform, combined different in-vitro and in-silico technologies, helps design and test potential treatments.

3. Rigorous Testing:
We conduct in-house studies and collaborate with partners to ensure the safety and efficacy of our products.

4. Regulatory Approvals:
We expertly navigate the regulatory landscape to secure the necessary certifications.

5. Global Market Expansion:
Our goal is to make our life-changing products accessible to patients worldwide.